ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements
Beta Drugs secured Azerbaijani regulatory approvals for its oncology portfolio across multiple dosage forms. The company targets Azerbaijan commercialisation during the current financial year.
Beta Drugs Limited has scheduled its 21st Annual General Meeting for September 30, 2026, at its registered office in Baddi, Himachal Pradesh.
Beta Drugs Limited announced the re-appointment of its Statutory Auditor and an Executive Director. These re-appointments are effective from September 2026 and January 2027, respectively.
Beta Drugs Limited announced its board meeting outcome, covering AGM arrangements, auditor appointments, and the re-appointment of its Whole-Time Director, Ashutosh Shukla.
Beta Drugs Ltd. reports Q1-FY27 revenue of INR 1,255 Mn with 21.83% EBITDA margin. Diversifying beyond core oncology into IVF via Nivian acquisition.
Beta Drugs delivered record EBITDA but missed revenue guidance due to delayed export tenders and strategic withdrawal from the low-margin Platin segment.
Beta Drugs delivered FY26 revenue of ₹385 Cr with a shift towards high-margin branded oncology (36% of mix) and 22.57% EBITDA margin.
Beta Drugs Ltd reported revenue from operations of ₹939,649,419 Cr (+0.2% YoY) and net profit of ₹90,489,234 Cr (+0.2% YoY) for Q4 FY26.